Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont - Wikidata - wikimedia - TriplyDB

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

http://www.wikidata.org/entity/Q34547981

about

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Adverse effects of biologics: a network meta-analysis and Cochrane overview Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)Combination therapy for pain management in inflammatory arthritis Biologics for rheumatoid arthritis: an overview of Cochrane reviews Adalimumab for treating rheumatoid arthritis Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Safety of extended treatment with anakinra in patients with rheumatoid arthritis Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.Biologic interventions for fatigue in rheumatoid arthritis Assessing the Immunogenicity of Biopharmaceuticals Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability Bone and TNF in rheumatoid arthritis: clinical implications Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies New insights into the impact of neuro-inflammation in rheumatoid arthritis Anti-TNF-alpha therapy and systemic vasculitis.Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy Rheumatoid arthritis: identifying and characterising polymorphisms using rat models Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort Adalimumab for the treatment of rheumatoid arthritis Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis TNF inhibitor therapy for rheumatoid arthritis Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis Incorporating data from various trial designs into a mixed treatment comparison model.[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data].Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence.

P2860

Q21134808-BC75B4D1-76DB-484C-A74E-A4E5A489F7A9 Q24185797-EEEDFCFD-69D7-4374-984A-F4AF47F94A81 Q24234197-A5C4580C-59D5-4B59-93B8-04F27E8CF840 Q24235846-9A3F5C1B-6799-4F36-AC2D-94B0F2805DD1 Q24236350-4717DC3A-550D-4611-9DAF-D8B90AE74F36 Q24240731-2AC3F25B-2698-4274-9B82-2507999DDF02 Q24246674-ED59A1CC-FCC7-40FA-92E0-DE79B78EE0D6 Q24630541-9622052B-5130-4383-BBD8-DBB3535B2EB8 Q24631295-AFC4E16B-C443-48EB-9B05-3223AFB0A1AD Q24675209-EF352C75-0181-4DF0-B60E-D12426D65208 Q24816844-E0BD384E-D45D-4686-9CB3-5CEF1F7D9934 Q26471538-DD509588-FDA7-48CB-8510-72AD212FB05F Q26751485-4E5A84DE-B9D8-4984-B195-79E9F2BB55DD Q26766368-5E20B167-EEFA-4A4F-B27A-CFB1E9B966B2 Q26771652-C5519527-3200-4136-9C6D-D334BAE2CB77 Q26777895-BA57229B-8BB8-449D-B763-DCD191401565 Q26778600-FF50971C-539B-4A05-92C2-55880858CEC2 Q26852235-EDE433BE-6ED4-4C9B-AF26-45358EE1BA74 Q26991673-4C483712-B955-4A87-811F-2DD9D7A42628 Q27023946-6CBADFD7-3FDA-4EDD-A4A4-D6F690567A71 Q27687590-958FCF49-93B8-4F26-B72C-8B468176710D Q27687777-A9145A1E-7E2A-48A4-B0C1-7E1DF43449FA Q27694496-E10C6AC4-F590-4A94-BBC8-716576C19727 Q28073099-86EC1191-C16A-4CD4-89AC-C901B121366D Q28271779-3F24B335-35BB-4082-BD87-9666F514D328 Q28282655-3BC351F9-17A6-4DAD-A036-9DE918F71F63 Q28484306-898AE572-928D-4E67-BB5D-DB70E0DE3516 Q28542901-CC593035-0148-475F-93FA-5F33DEC11160 Q28543128-0A67DAE7-C4D9-4F89-A8AF-0D8AF90642DE Q28547851-C5CF953A-FA40-4F74-927E-D0E96ACA837D Q28972424-127E0A36-8D7B-4C94-BB21-4741093B6B7D Q30234528-F70178EA-EC29-4829-90F3-FA9186A5CF27 Q30235341-3870FD22-ACEC-4731-8879-EEB45437F70C Q30240183-672367C9-C476-4A49-A53A-AA935E51859B Q30240212-8D7E7B23-B304-4A61-BF87-E06D366389FE Q30576366-9C3B6732-0CAF-470C-B728-9B924644CBE2 Q30594247-0BED3658-36ED-446B-82F9-A4DC75A3EF8E Q30699616-D2A4298E-CA9F-422D-9E45-0614E73590F8 Q30839439-3B96A903-24D9-4C0A-989F-2438815B77F3 Q30872562-4B0091E0-5307-4BD5-AADE-5EC4E300EED5

P2860

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

http://www.wikidata.org/entity/Q34547981

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@ast

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@en

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@nl

type

label

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@ast

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@en

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@nl

prefLabel

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@ast

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@en

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@nl

P1433

Q34547981-5E66DC9D-CF6B-4967-8428-4CE39346BC1C

P1476

Q34547981-80372BFA-7C10-4863-93BD-5BD0AF9B6673

P2093

Q34547981-0B1A0B07-8C81-4A8A-858E-B44794B3E554

Q34547981-286E3F15-835B-417D-B638-3009F6319BD1

Q34547981-538C6998-038B-4E64-9C06-628A4CDA7404

Q34547981-6608D345-B853-4D36-AE0B-E7873AFA7EEF

Q34547981-7D4D86D3-85EA-4B12-9549-18D94D92E6FB

Q34547981-934BB46A-2FD6-45D0-A0C7-EAA6C6A22649

Q34547981-97D0F670-DC0E-4BA5-B499-27A202DD7AF8

Q34547981-CFDF6816-0BE6-4840-9C81-7FF77415D17E

P304

Q34547981-AFAC5CF1-536E-4351-B71F-6650E805E6AD

P31

Q34547981-3E0CCA10-89C0-4B9E-8F85-AC00CFC220CC

P356

Q34547981-00C86789-5707-49F1-88F7-6A80F33CE658

P433

Q34547981-BEF759CD-CF7E-4BD1-A9D1-270B363EA5DE

P478

Q34547981-5D55E8C7-A48A-4FE5-BE17-B458A67AEE2D

P577

Q34547981-AD3BE926-4CA8-47B1-8673-5F382DE0544E

P5875

Q34547981-0929719F-CDCF-43A3-9139-26E46912D97B

P698

Q34547981-42B6D4C2-612D-4DEF-A104-4E04636F276A

P921

Q34547981-184B2195-2850-49DE-A315-5682A2781D3F

Q34547981-23402ED1-6898-4827-8238-4A63E890534A

Q34547981-2C68CD1F-B1CF-43FA-9ABF-2386C0FA39DA

Q34547981-DAA9D372-9C13-41BD-A76C-70662AB1020D

P356

P1433

Arthritis & Rheumatology

P1476

Radiographic, clinical, and fu ...... py: a randomized, placebo-cont

@en

P2093

Arthur F Kavanaugh

http://www.w3.org/2001/XMLSchema#string

Edward C Keystone

http://www.w3.org/2001/XMLSchema#string

Elliot K Chartash

http://www.w3.org/2001/XMLSchema#string

Hyman Tannenbaum

http://www.w3.org/2001/XMLSchema#string

John T Sharp

http://www.w3.org/2001/XMLSchema#string

Leah S Teoh

http://www.w3.org/2001/XMLSchema#string

Steven A Fischkoff

http://www.w3.org/2001/XMLSchema#string

Ye Hua

http://www.w3.org/2001/XMLSchema#string

P304

1400-1411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.20217

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8560548

http://www.w3.org/2001/XMLSchema#string

P698

15146409

http://www.w3.org/2001/XMLSchema#string

P921